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Abstract
Influenza A viruses can adapt to new host species, leading to the emergence of novel pathogenic strains. There is evidence
that highly pathogenic viruses encode for non-structural 1 (NS1) proteins that are more efficient in suppressing the host
immune response. The NS1 protein inhibits type-I interferon (IFN) production partly by blocking the TRIM25 ubiquitin E3
ligase-mediated Lys63-linked ubiquitination of the viral RNA sensor RIG-I, required for its optimal downstream signaling. In
order to understand possible mechanisms of viral adaptation and host tropism, we examined the ability of NS1 encoded by
human (Cal04), avian (HK156), swine (SwTx98) and mouse-adapted (PR8) influenza viruses to interact with TRIM25
orthologues from mammalian and avian species. Using co-immunoprecipitation assays we show that human TRIM25 binds
to all tested NS1 proteins, whereas the chicken TRIM25 ortholog binds preferentially to the NS1 from the avian virus.
Strikingly, none of the NS1 proteins were able to bind mouse TRIM25. Since NS1 can inhibit IFN production in mouse, we
tested the impact of TRIM25 and NS1 on RIG-I ubiquitination in mouse cells. While NS1 efficiently suppressed human
TRIM25-dependent ubiquitination of RIG-I 2CARD, NS1 inhibited the ubiquitination of full-length mouse RIG-I in a mouse
TRIM25-independent manner. Therefore, we tested if the ubiquitin E3 ligase Riplet, which has also been shown to
ubiquitinate RIG-I, interacts with NS1. We found that NS1 binds mouse Riplet and inhibits its activity to induce IFN-b in
murine cells. Furthermore, NS1 proteins of human but not swine or avian viruses were able to interact with human Riplet,
thereby suppressing RIG-I ubiquitination. In conclusion, our results indicate that influenza NS1 protein targets TRIM25 and
Riplet ubiquitin E3 ligases in a species-specific manner for the inhibition of RIG-I ubiquitination and antiviral IFN production.
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Introduction
Influenza A viruses (IAVs) are highly infectious pathogens that
have caused major pandemics and annual epidemics with serious
economic and health consequences [1,2]. IAVs are naturally
maintained in avian species but they also circulate in humans,
horses,dogsand pigs [3].Although multigenichostrangerestrictions
exist, a combination of viral determinants can ultimately allow a
virus to establish infection in a specific host [4]. This is particularly
important because, although the current highly pathogenic avian
IAVs that havebeen transmitted to humanslackthe ability to spread
from human to human, there is current concern that these avian
virusesmayadapt anddevelop the ability to spreadefficientlyamong
humans.Inthisrespect, recent studieshavedemonstratedthat onlya
few mutations in the hemagglutinin (HA) allow for transmissibility of
highly pathogenic H5N1 viruses in ferrets [5,6]. Moreover, pigs can
be infected with human and avian viruses and provide an
environment for reassortment and the generation of new influenza
virus strains capable of human transmission [7]. Therefore, it is
essential to better understand the mechanisms that allow influenza
viruses to adapt to a new host species, in order to predict and protect
from future cross-species transmission.
IAV is an enveloped virus that harbors a negative-strand RNA
genome encoding eleven different proteins from 8 separate
segments [8]. Individual viral proteins play critical roles in
species-specific pathogenicity. For example, the hemagglutinin
(HA) protein which binds in a species-dependent manner to sialic
acid on host cell membranes; the neuraminidase (NA) protein
which is important for viral release; and the polymerase
components (PA, PB1, PB2) which are important for efficient
replication [9]. The non-structural protein 1 (NS1), which is the
product of the smallest RNA segment, acts as a virulence factor by
inhibiting host immune responses [10–15]. An important host
innate immune mechanism is the production of type-I interferons
(IFNs), which can establish an antiviral state by up-regulating
interferon stimulated genes (ISGs) that interfere with distinct steps
in the viral life cycle [16,17].
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produced when host pattern recognition receptors (PRRs),
including Toll-like receptors (TLRs) and RIG-I-like receptors
(RLRs), recognize pathogen-associated molecular patterns
(PAMPs) such as nucleic acids or other structural components of
the microbe [18–21]. Viral single-stranded or short double-
stranded RNA bearing a 59-triphosphate is recognized by the
cytosolic RNA helicase RIG-I [22,23]. In addition, next-genera-
tion RNA sequencing revealed that in influenza A virus infected
cells RIG-I preferentially associated with the shorter genomic
segments as well as subgenomic defective interfering particles [24].
RIG-I is composed of two N-terminal caspase recruitment
domains (CARDs), a central DExD/H box helicase/ATPase,
and a C-terminal regulatory domain (CTD/RD). Under normal
conditions, RIG-I is in an inactive, closed conformation. Upon
RNA recognition, exposure of the N-terminal CARDs of human
RIG-I leads to Lys63-linked ubiquitination on Lys172 induced by
tripartite motif 25 (TRIM25) ubiquitin E3 ligase. The ubiquiti-
nated CARDs then allow RIG-I binding to MAVS (also called
IPS-1, Cardif, or VISA) and thereby downstream signaling for
IRF3 phosphorylation and type-I IFN production [25]. Another
ubiquitin E3 ligase, Riplet (or RNF135), has also been reported to
ubiquitinate RIG-I and promote its signal transducing ability for
antiviral IFN production [26,27]. Specifically, Riplet was shown to
activate RIG-I by inducing Lys63-linked ubiquitination of the
lysine residues 849 and 851 in the RIG-I CTD [26,27].
Many viruses are equipped with specialized mechanisms to
suppress the host type-I IFN system. Influenza A viruses through
their NS1 protein can inhibit type-I IFN production by various
mechanisms, including inhibition of RIG-I [23,28–30] and, in
some cases suppressing general host gene expression by targeting
the 30 kDa subunit of cleavage and polyadenylation specificity
factor (CPSF30) [31–33]. The importance of this mechanism of
antagonism is further supported by the fact that some highly
pathogenic viruses encode NS1 proteins that are more efficient in
suppressing the host antiviral response. For example, the NS1
protein of the highly pathogenic 1918 virus blocked the expression
of IFN-regulated genes more efficiently than the NS1 from
influenza A/WSN/33 virus [11]. In addition, the NS1 gene of a
human IAV, when passaged in mouse, accumulated adaptive
mutations that resulted in increased virulence and IFN antagonism
[34]. Importantly, in addition to NS1, also other viral genes,
including PA, PB1, PB2 and PB1-F2 have been shown to exert
IFN-antagonistic functions [35–37].
We have recently uncovered the mechanism of RIG-I inhibition
by NS1 [38]. NS1 binds to the central coiled-coil (CCD) region of
TRIM25 ubiquitin E3 ligase, blocking its oligomerization and
enzymatic activity to induce Lys63-linked ubiquitination of the
RIG-I CARDs. NS1 thereby inhibits RIG-I CARD-dependent
downstream signaling [38]. However there are differences in PRR
signaling components of different species that could impact NS1
immunosuppressive function. For example, mouse RIG-I lacks
Lys172, which has been previously shown to be essential for
ubiquitination-dependent activation of human RIG-I [25]. In
addition, it appears that chicken lacks a functional RIG-I gene
[39]. This host specificity in the RIG-I antiviral signaling pathway
may provide a barrier for new incoming viruses, which in turn will
need to adapt to inhibit these host-specific immune responses.
In this study, we examined the ability of NS1 encoded by
human (Cal04), avian (HK156), swine (SwTx98), and mouse (PR8)
adapted influenza A viruses to interact with TRIM25 orthologues
from mammalian and avian species, and the impact that this
interaction has in regulating the RIG-I-mediated type-I IFN
response. We found that while NS1 efficiently inhibits TRIM25-
mediated RIG-I ubiquitination and activation in human cells, in
murine cells NS1 targets the ubiquitin E3 ligase Riplet to suppress
RIG-I ubiquitination and signal transducing activity. Further-
more, we identified that the NS1 proteins of human viruses have
evolved to bind and antagonize both human TRIM25 and human
Riplet for the potent inhibition of the RIG-I-mediated IFN
response.
Results
Influenza A Virus NS1 Protein Interacts with TRIM25 in a
Species-specific Manner
Given that mammalian and avian TRIM25 proteins show
significant differences in their CCD (Supplemental Figure S1A),
that in the case of human TRIM25 is necessary and sufficient for
NS1 binding [38], we tested the ability of NS1 encoded by human
(A/California/04/09 [Cal04]), avian (A/Hong Kong/156/1997
[HK156]), swine (A/Swine/Texas/4199-2/98 [SwTx98]) and
mouse-adapted (A/Puerto Rico/8/34 [PR8]) influenza A viruses
to interact with TRIM25 orthologues. To facilitate these studies,
we used NS1 proteins that lack the ability to bind CPSF30 and
therefore are unable to block general host gene expression [40].
Furthermore, these NS1 proteins have conserved E96/E97 amino
acids previously shown to be important for interaction with human
TRIM25 (Supplemental Figure S1B) [38].
Consistent with our previous results [38], co-immunoprecipita-
tion (Co-IP) studies in transfected HEK293T cells showed that all
tested NS1 proteins efficiently interacted with human TRIM25
(hTRIM25) (Figure 1A). Furthermore, chicken TRIM25
(chTRIM25) bound strongly to NS1-HK156, whereas only a
weak or no interaction with chTRIM25 was observed for NS1
from PR8 or Cal04 and SwTx98, respectively (Figure 1A).
Moreover, none of the NS1 proteins interacted with mouse
TRIM25 (mTRIM25).
It has been suggested that chicken lacks a functional RIG-I gene
[39]. We thus asked whether chTRIM25 is important for IFN-b
induction upon IAV infection, and further tested if the
chTRIM25-NS1 interaction is functional. To this end, we silenced
Author Summary
Influenza viruses cause annual epidemics and occasionally,
major global pandemics. To establish productive infection
these viruses have mechanisms to evade host immune
responses, including the type-I interferon (IFN) response.
An important component of the IFN system is the helicase
RIG-I that recognizes viral RNA, and is subsequently
ubiquitinated by TRIM25 ubiquitin E3 ligase to induce
downstream signaling resulting in IFN-a/b production. The
NS1 protein of influenza A viruses binds to human TRIM25
and inhibits TRIM25-dependent RIG-I ubiquitination and
downstream RIG-I signaling. An important unresolved
question is how viruses can inhibit the RIG-I pathway
when infecting new hosts. Here we show that while
human TRIM25 is able to bind to different NS1 proteins,
chicken TRIM25 binds preferentially to the NS1 from an
avian virus. Strikingly, mouse TRIM25 was unable to bind
NS1. We found that NS1 blocks RIG-I signaling in mouse
and human cells by different mechanisms. While NS1
inhibits human TRIM25-mediated RIG-I ubiquitination, in
mouse cells NS1 suppresses RIG-I signaling by binding to
and inhibiting the ubiquitin E3 ligase Riplet. These results
help understand the immune evasion strategies used by
influenza virus in different species, and may partly explain
the ability of this virus to adapt to different host species.
Species-Specific RIG-I Inhibition by Influenza NS1
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mRNA expression upon viral infection (Figures 1B–1D). Specif-
ically, we used recombinant A/PR/8/34 viruses expressing NS1
proteins from PR8, SwTx98, and HK156, which showed
differential binding to chTRIM25, as well as a PR8 recombinant
virus expressing the NS1 mutant R38A/K41A, known to be
deficient in IFN antagonism due to its abolished dsRNA and
hTRIM25 binding ability [10,38,41]. Approximately 87% knock-
down of chTRIM25 mRNA levels was achieved as determined by
quantitative PCR (qPCR) (Figure 1B). Compared to mock-infected
control cells, IFN-b mRNA was highly up-regulated (,1500-fold)
upon infection with the NS1 mutant R38A/K41A virus
(Figure 1C). This IFN-b induction was significantly reduced in
TRIM25-knockdown LMH cells, suggesting that TRIM25 is
indeed functional in chicken cells. In addition, IFN-b induction
upon infection with PR8, SwTx98 and HK156 recombinant
viruses inversely correlated with the ability of their NS1 proteins to
bind chTRIM25 (Figure 1D). While PR8 and HK156 were poor
inducers of IFN-b mRNA, infection with SwTx98 virus, whose
NS1 protein did not bind chTRIM25, resulted in ,15-fold IFN-b
induction. Furthermore, the IFN-b induction by SwTx98 virus
was reduced to almost basal levels in TRIM25-knockdown cells,
indicating that this virus induces IFN-b gene expression in chicken
cells by a mechanism mostly dependent on TRIM25 (Figure 1D).
To exclude that the low levels of IFN production induced by the
PR8 and HK156 viruses are due to inefficient replication in LMH
cells, we measured the mRNA levels of viral M1 by qPCR
(Figure 1E). All viruses replicated well, and although only minor
differences were observed, the levels of M1 mRNA inversely
correlated with the IFN-b inducing activity of these viruses. This
Figure 1. Influenza A Virus NS1 interacts with TRIM25 in a species-specific manner. (A) HEK293T cells were transfected with V5-tagged
mouse TRIM25 (V5-mTRIM25), human TRIM25 (V5-hTRIM25) or chicken TRIM25 (V5-chTRIM25) together with NS1-A/California/04/09 (Cal04) (left), or
NS1-PR8, NS1-A/Hong Kong/156 (HK156), NS1-A/Swine Texas/98 (SwTx98), or NS1-Cal04 (right panel). Empty vector and V5-tagged human TRIM21
were used as negative controls. Whole-cell lysates (WCLs) of HEK293T cells were subjected to immunoprecipitation (IP) using anti-V5 antibody,
followed by immunoblotting (IB) with anti-NS1. (B–E) TRIM25 is important for virus-induced IFN-b production in chicken cells. Chicken LMH cells were
transiently transfected with non-silencing control siRNA (si.C), or with a siRNA specific for chicken TRIM25 (si.chTRIM25). At 40 h posttransfection, cells
were infected with recombinant influenza viruses expressing the NS1 RNA-binding mutant R38A/K41A (C), or NS1 from PR8, SwTx98, or HK156 (D)a t
an MOI of 0.1 for 24 h. Knockdown was confirmed by determining chTRIM25 mRNA levels (B). Furthermore, the IFN-b (C and D) and viral M1 (E)
mRNA levels were assessed by qPCR and the values were normalized to chicken GAPDH. (F) IFN induction and viral replication in murine (MEF) cells.
12 hours postinfection, IFN-b (far left panel) and viral M1 (right panel) mRNA levels were assessed by qPCR from MEFs infected with the different NS1
recombinant viruses at an MOI of 2. Values were normalized to mouse actin. IFN protein was quantified by VSV-GFP bioassay on L929 cells treated
with 2-fold dilutions of post-influenza virus supernatants from MEF cells (left panel). Relative fluorescence values reported on the y-axis represent the
levels of VSV-GFP replication. High IFN concentrations in the supernatants correspond to low levels of VSV-GFP replication (low fluorescence values).
Each sample was assayed in triplicate, and results are representative of two independent experiments. Supernatants were assayed for progeny virus
yields 12 h postinfection in standard plaque titrations (far right panel). Virus yields are depicted in PFU/ml. *p,0.05; ***p,0.001.
doi:10.1371/journal.ppat.1003059.g001
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an antiviral response in chicken cells.
We next tested whether the inability of the NS1 proteins to
bind mTRIM25 correlates with their IFN-inducing activities in
mouse cells. For this, we infected murine embryonic fibroblasts
(MEF) with the different NS1 recombinant viruses. IFN-b mRNA
induction was then determined by qPCR, and IFN protein levels
were measured by bioassay (Figure 1F, left panels). Surprisingly,
although none of the NS1 proteins bound to mTRIM25
(Figure 1A), all NS1 recombinant viruses induced very low
amounts of IFN in MEFs as compared to the R38A/K41A
mutant virus, suggesting that NS1 does not require binding to
TRIM25 for suppressing IFN induction in murine cells. Binding
of NS1 to CPSF30 could also not account for this inhibitory
activity in MEFs, as all of these NS1 proteins are deficient in
inhibiting CPSF30 and thus general gene expression [40].
Furthermore, all viruses replicated to similar levels in the MEF
cells as determined by M1 mRNA and virus titrations (Figure 1F,
right panels).
Mice are frequently used as a model to study influenza
pathogenesis. It is therefore important to understand the detailed
mechanisms by which influenza virus escapes the immune
response in this particular host. Thus, we first sought to confirm
the lack of NS1 interaction with mTRIM25. To rule out that the
inability of NS1 to bind to mTRIM25 was due to the absence of a
co-factor required for NS1-TRIM25-interaction in human cells,
we tested the binding of NS1-PR8 to endogenous TRIM25 in
PR8-infected human HEK293T and murine Hepa1.6 cells
(Figure 2A). NS1 efficiently interacted with endogenous TRIM25
in HEK293T cells, whereas it did not bind to endogenous
TRIM25 in Hepa1.6 cells (Figure 2A). We also observed an
efficient interaction of ectopically expressed NS1 with exogenous
hTRIM25, but not with mTRIM25, in HEK293T and Hepa1.6
cells (Figure 2B). In line with this, bacterially purified Glutathione-
S-transferase (GST)-NS1 fusion protein bound to hTRIM25, but
not to mTRIM25, in an in vitro binding assay (Figure 2C).
The CCDs of human and mouse TRIM25 proteins share only
56% identity at the amino acid level (aa 180–450) with major
Figure 2. Influenza A Virus NS1 does not interact with mouse TRIM25. (A) WCLs of human (HEK293T) or mouse (Hepa1.6) cells, that had
been mock-treated or infected with PR8 virus at MOI 2 for 18 h, were subjected to IP with or without anti-NS1 antibody, followed by IB with anti-
TRIM25. Expression of NS1 and endogenous TRIM25 was determined by IB with anti-NS1 or anti-TRIM25 antibody. (B) Mouse Hepa1.6 or human
HEK293T cells were transfected with empty vector, V5-tagged mouse TRIM25 (V5-mTRIM25), or V5-tagged human TRIM25 (V5-hTRIM25), together
with NS1-PR8. At 30 h posttransfection, WCLs were prepared and subjected to IP with anti-V5 antibody, followed by immunoblotting with anti-NS1 or
anti-V5. (C) In vitro binding of NS1 with TRIM25. Maltose-binding protein (MBP), GST, and the recombinant fusion proteins MBP-human TRIM25-Flag
(MBP-hTRIM25-Flag), MBP-mouse TRIM25-Flag (MBP-mTRIM25-Flag), and GST-NS1 (PR8) were purified from bacteria. Purified MBP-hTRIM25-Flag or
MBP-mTRIM25-Flag was incubated with GST-NS1. As controls for binding, purified MBP was incubated with GST-NS1, and MBP-hTRIM25-Flag was
incubated with GST. Protein complexes were then precipitated with Amylose agarose gel, and precipitates resolved by SDS-PAGE, followed by
Coomassie staining. Asterisk indicates the main degradation product of MBP-hTRIM25-Flag.
doi:10.1371/journal.ppat.1003059.g002
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changes in TRIM25 CCD are responsible for the difference in
NS1 binding we generated a human/mouse chimeric TRIM25
protein containing amino acids 191–379 of hTRIM25
(mChimT25h191–379) and analyzed its ability to interact with
NS1-PR8 (Figures 3A and 3B). Co-IP experiments showed that
while mTRIM25 did not interact with NS1, hTRIM25 and the
mChimT25h191–379 efficiently bound NS1 (Figure 3B).
As previously reported [38], overexpressed NS1 localizes
primarily to the nucleus with a minor cytoplasmic component;
however, co-expressed hTRIM25 led to a marked increase of NS1
cytoplasmic localization, indicative of hTRIM25-NS1 interaction.
As shown in Figures 3C and 3D, ectopic expression of hTRIM25
or mChimT25h191–379 markedly re-localized NS1 to the cyto-
plasm, where they extensively co-localized (92% and 80% of cells
with cytoplasmic NS1, respectively). In contrast, co-expression of
mTRIM25 that did not interact with NS1 showed only a minor
effect on NS1 sub-cellular localization (Figures 3C and 3D). These
results collectively demonstrate that amino acid changes in the
CCD region of mouse TRIM25 are responsible for the loss of
interaction with NS1.
NS1-PR8 Inhibits Mouse RIG-I Ubiquitination and
Downstream IFN Induction in a TRIM25-independent
Manner
Influenza A viruses lacking functional NS1 proteins induce a
robust IFN response, and thus replicate poorly in immunocom-
petent mice, indicating that NS1 inhibits induction of IFN in mice
[42]. However, while in human cells NS1 interacts with human
TRIM25 for inhibition of RIG-I ubiquitination and activation
[38], the same mechanism cannot apply to mouse cells, as NS1
Figure 3. Chimeric mouse TRIM25 containing the CCD of human TRIM25 recovers NS1 binding. (A) Schematic representations of human
TRIM25 (hT25), mouse TRIM25 (mT25) and the mouse/human TRIM25 chimera (mChimT25h191–379). Numbers indicate amino acid. (B) WCLs of
HEK293T cells, that had been transfected with empty vector, V5-hTRIM25, V5-mTRIM25 or V5-mChimT25h191–379 together with NS1-PR8, were
subjected to IP with anti-V5 antibody, followed by IB with anti-NS1. (C) Localization of NS1-PR8 in HeLa cells determined by confocal microscopy. At
30 h posttransfection with NS1-PR8 alone, NS1-PR8 together with V5-hTRIM25, V5-mTRIM25, or V5-mChimT25h191–379, HeLa cells were stained with
anti-NS1 (green), anti-V5 (red) and DAPI (nucleus, blue). (D) Quantification of cytoplasmic NS1 localization from (C). From three independent
experiments, 50 cells with expression of NS1 alone or NS1 together with hTRIM25, mTRIM25 or mChimT25h191–379, respectively, were counted and the
percentage of cells with cytoplasmic NS1 is shown, ***p,0.001 by Fisher’s exact test.
doi:10.1371/journal.ppat.1003059.g003
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insights on the impact of NS1 on mouse RIG-I activation we
examined the effect of NS1 on the ubiquitination of human or
mouse RIG-I 2CARD in human HEK293T or mouse Hepa1.6
cells (Figure 4A).
Consistent with our previous results [38], NS1-PR8 potently
inhibited the ubiquitination of GST-fused human RIG-I 2CARD
(GST-hRIG-I 2CARD) in HEK293T cells in a dose-dependent
manner. In striking contrast, NS1 did not block the ubiquitination
of mouse GST-RIG-I 2CARD (GST-mRIG-I 2CARD) in
Hepa1.6 cells (Figure 4A). Furthermore, we analyzed the effect
of NS1 on the Sendai virus (SeV)-induced ubiquitination of full-
length RIG-I in human HEK293T and murine Hepa1.6 cells
(Figure 4B). Interestingly, exogenously expressed NS1-PR8
effectively suppressed the ubiquitination of full-length RIG-I in a
dose-dependent manner in both cell lines (Figure 4B). These
results collectively suggest that while NS1 efficiently inhibits the
CARD ubiquitination of human RIG-I, it suppresses the
ubiquitination of mouse RIG-I by acting on its C-terminal region.
Lys172 in the CARDs of human RIG-I (hRIG-I) is essential for
RIG-I ubiquitination and activation by TRIM25 [25]. However,
this residue is not conserved in mouse RIG-I (mRIG-I) (Supple-
mental Figure S2), raising the question whether mRIG-I is
ubiquitinated by mTRIM25 as previously reported to occur for
human RIG-I. Strikingly, ubiquitination of GST-h2CARD was
undetectable in TRIM25 2/2 MEFs, whereas it was robustly
ubiquitinated in wild-type (WT) MEFs (Figure 5A). In contrast,
GST-m2CARD showed a decreased but still detectable ubiquiti-
Figure 4. NS1 inhibits the ubiquitination of full-length RIG-I but not that of RIG-I 2CARD in murine cells. (A) Human HEK293T (left)o r
mouse Hepa 1.6 (right) cells were transfected with human GST-RIG-I 2CARD (GST-hRIG-I 2CARD) (left) or mouse GST-RIG-I 2CARD (GST-mRIG-I
2CARD) (right) and increasing amounts of NS1-PR8 (left and right). At 40 h posttransfection, WCLs were subjected to GST-pulldown (GST-PD),
followed by IB with anti-GST antibody. Arrow heads indicate ubiquitinated bands. Arrow indicates non-ubiquitinated 2CARD. (B) Human HEK293T
(left) or mouse Hepa1.6 (right) cells were transfected with Flag-tagged human RIG-I (Flag-hRIG-I) or Myc-tagged mouse RIG-I (Myc-mRIG-I)
respectively, together with empty vector or HA-ubiquitin and increasing amounts of NS1-PR8. At 24 h posttransfection, cells were infected with SeV
(10 HA units/ml) for 10 h. WCLs were subjected to IP with anti-Flag (left) or anti-Myc (right), followed by IB with the indicated antibodies.
doi:10.1371/journal.ppat.1003059.g004
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PLOS Pathogens | www.plospathogens.org 6 November 2012 | Volume 8 | Issue 11 | e1003059Figure 5. NS1-mediated suppression of RIG-I ubiquitination and IFN induction in mouse is TRIM25-independent. (A) Ubiquitination of
the RIG-I CARDs in WT and TRIM25 2/2 MEF cells. WT and TRIM25 2/2 MEFs were transfected with human GST-RIG-I 2CARD (GST-h2CARD) or mouse
GST-RIG-I 2CARD (GST-m2CARD). At 40 h posttransfection, WCLs were subjected to GST-pulldown (GST-PD), followed by IB with anti-GST antibody.
Arrow heads indicate ubiquitinated bands. Arrow indicates non-ubiquitinated 2CARD. (B) Ubiquitination of the RIG-I CARDs in TRIM25 2/2 cells
reconstituted with mouse or human TRIM25. At 40 h posttransfection with human or mouse GST-RIG-I 2CARD together with empty vector, V5-tagged
hTRIM25 or mTRIM25, WCLs of TRIM25 2/2 MEFs were subjected to GST-PD, followed by IB with anti-GST or anti-ubiquitin (Ub) antibody. Expression
of TRIM25 proteins was determined by IB with anti-V5 antibody. Arrow heads indicate ubiquitinated bands. Arrow indicates non-ubiquitinated
2CARD. (C) NS1 inhibits the RIG-I CARD ubiquitination induced by human TRIM25 but not by mouse TRIM25. TRIM25 2/2 MEFs were transfected with
GST, human GST-RIG-I 2CARD (GST-h2CARD) or mouse GST-RIG-I 2CARD (GST-m2CARD) together with vector, hTRIM25-V5 or mTRIM25-V5 with or
without NS1. At 40 h posttransfection, WCLs were subjected to GST-PD, followed by IB with anti-GST for detecting RIG-I CARD ubiquitination, anti-V5
for detecting TRIM25 binding, or anti-NS1 antibody for detecting NS1 binding. Arrow heads indicate ubiquitinated bands. Arrow indicates non-
ubiquitinated 2CARD. (D) NS1 interacts with mouse RIG-I in a TRIM25-independent manner. TRIM25 2/2 MEFs were transfected with empty vector,
V5-hTRIM25, or V5-mTRIM25 together with NS1-PR8. WCLs were subjected to IP with anti-RIG-I antibody, followed by IB with anti-NS1, anti-V5, or
anti-RIG-I antibody. Expression of NS1 and TRIM25 proteins in the WCLs was determined by anti-NS1 and anti-V5 antibody, respectively. (E) NS1
inhibits endogenous mouse RIG-I ubiquitination in a TRIM25-independent manner. TRIM25 2/2 MEFs were transfected with increasing amounts of
NS1-PR8. At 32 h posttransfection, cells were infected with SeV (50 HA units/ml) for 10 h. WCLs were subjected to IP with anti-RIG-I antibody,
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(Figure 5A). Reconstitution of TRIM25 2/2 MEFs with mouse
or human TRIM25 showed an increase in both human and mouse
RIG-I 2CARD ubiquitination (Figure 5B), indicating that
mTRIM25 is active and is able to ubiquitinate the mouse RIG-I
CARDs under these conditions at a different Lys residue/s.
Interestingly, NS1 inhibited the hTRIM25-dependent ubiquitina-
tion of human or mouse RIG-I 2CARD but was unable to inhibit
mTRIM25-dependent ubiquitination of human or mouse RIG-I
2CARD (Figure 5C). In support of this, NS1 co-immunoprecip-
itated with RIG-I 2CARD only when hTRIM25 was present, but
not in the presence of ectopically expressed mTRIM25 (Figure 5C).
Since NS1 potently inhibited the ubiquitination of full-length
mRIG-I (Figure 4B), we next tested if NS1-PR8 interacts with
endogenous RIG-I in non-complemented TRIM25 2/2 MEFs,
or in TRIM25 2/2 MEFs reconstituted with either human or
mouse TRIM25 (Figure 5D). This showed that NS1 readily co-
immunoprecipitated with endogenous RIG-I in TRIM25 2/2
MEFs, and this interaction was further increased in the presence of
exogenous human but not mouse TRIM25 (Figure 5D). Further-
more, exogenously expressed NS1-PR8 strongly suppressed the
SeV-induced ubiquitination of endogenous RIG-I in TRIM25 2/
2 cells in a dose-dependent manner (Figure 5E), indicating that
NS1 binds to mouse RIG-I and inhibits its ubiquitination in a
TRIM25-independent manner. We next determined the ubiqui-
tination of endogenous RIG-I in WT and TRIM25 2/2 MEFs
upon PR8 virus infection (Supplemental Figure S4A). This showed
that RIG-I ubiquitination was decreased in TRIM25 2/2 MEFs
compared to WT MEFs. Furthermore, PR8 infection markedly
reduced the ubiquitination of endogenous RIG-I in both WT
MEFs and TRIM25 2/2 MEFs (Supplemental Figure S4A).
Finally, we examined the ability of NS1-PR8 to inhibit IFN-b
promoter activation in WT MEFs or TRIM25 2/2 MEFs. As
expected, NS1 inhibited SeV-induced IFN-b promoter activation
in WT MEFs (Figure 5F). TRIM25 2/2 MEFs showed a
markedly reduced IFN-b promoter activity upon SeV infection as
compared to WT MEFs; however there was still detectable IFN-b
induction by SeV stimulation. This residual IFN-b induction in
TRIM25 2/2 MEFs was further suppressed by exogenous NS1
(Figure 5F), demonstrating that NS1 inhibits the IFN induction in
mouse cells by a TRIM25 independent mechanism.
Collectively, these results demonstrate that human TRIM25 is
the major ubiquitin E3 ligase for human RIG-I 2CARD and that
NS1 inhibits its activity. Our results further indicate that in mouse
cells there is an alternative ubiquitin E3 ligase that cooperates with
TRIM25 for full activation of mouse RIG-I, and that this
alternative ubiquitin E3 ligase is probably targeted by NS1.
NS1 Interacts with Mouse Riplet Ubiquitin E3 Ligase
Riplet (also known as RNF135) has recently been shown to be
important for IFN production in mice [27] and to ubiquitinate
human RIG-I at Lys849 and Lys851 in its C-terminal domain
[26]. Since these lysine residues are conserved in mouse RIG-I
(Supplemental Figure S3) we hypothesized that NS1 may bind
mouse Riplet (mRiplet), thereby suppressing RIG-I ubiquitination
and downstream signaling in mouse.
As shown in Figure 6A, NS1-PR8 readily bound exogenously
expressed mRiplet in HEK293T cells in the presence or absence of
SeV infection. We also observed an efficient interaction of NS1
with mRiplet in Hepa1.6 cells infected with the PR8 strain
(Figure 6B). Immunofluorescence assays further showed that, as
seen with human TRIM25, co-expressed mRiplet re-localized
NS1 from the nucleus to the cytoplasm; approximately 90% of the
cells exhibited primarily cytoplasmic NS1 (Figure 6C). Further-
more, exogenously expressed NS1 of Cal04 and HK156 strains
also efficiently interacted with mRiplet in murine Hepa1.6 cells
(Supplemental Figure S4B). In addition, Hepa1.6 cells infected
with various recombinant A/PR/8/34 viruses expressing NS1
proteins from PR8, Cal04, HK156, Tx91, SwTx98, and Pan99,
also showed an interaction between NS1 and mRiplet (Figure 6D),
indicating that this effect is not exclusive of the NS1 protein of the
mouse-adapted PR8 strain. Finally, the NS1 E96A/E97A mutant
that lacks the ability to bind human TRIM25 [38] was also able to
interact with mRiplet in transfected and infected cells, whereas the
NS1 R38A/K41A mutant, lacking both dsRNA and hTRIM25
binding, did not bind to mRiplet under the same conditions
(Figure 6E and Supplemental Figure S4C).
NS1 Antagonizes the Riplet-dependent RIG-I
Ubiquitination and IFN Induction in Murine Cells
We next asked whether NS1 specifically suppresses the Riplet-
mediated ubiquitination of RIG-I in murine cells. For this, we
examined the endogenous RIG-I ubiquitination in murine
Hepa1.6 cells that were transfected with empty vector or Flag-
mRiplet together with or without NS1-PR8 (Figure 7A). This
showed that exogenous expression of mRiplet markedly enhanced
the ubiquitination of endogenous RIG-I, and this ubiquitination
was potently suppressed by co-expression of NS1 (Figure 7A).
Consistent with this, ectopic expression of mRiplet led to a 4.6-fold
increase of mRIG-I-induced IFN-b promoter activation, and this
RIG-I activation was inhibited almost to basal levels by co-
expressed NS1 (Figure 7B). Finally, we sought to determine the
role of endogenous Riplet in mouse RIG-I ubiquitination, and also
addressed whether NS1 specifically antagonizes the mRiplet-
induced RIG-I ubiquitination. For this, we examined the
ubiquitination of RIG-I in Hepa1.6 cells in which endogenous
Riplet was silenced using specific siRNA (Figure 7C). 78%
knockdown efficiency was achieved as determined by RT-PCR
analysis compared to non-silencing control siRNA (data not
shown). Specific knockdown of endogenous Riplet strongly
decreased endogenous RIG-I ubiquitination (Figure 7C). Further-
more, co-expressed NS1 efficiently blocked the ubiquitination of
RIG-I in cells transfected with non-silencing control siRNA, while
NS1 had no effect on the residual ubiquitination of RIG-I
observed in Riplet-knockdown cells (Figure 7C). These results
collectively demonstrate that Riplet is an important ubiquitin E3
ligase for mouse RIG-I, and that NS1 specifically targets Riplet to
inhibit RIG-I ubiquitination in murine cells.
To further demonstrate that Riplet contributes to the establish-
ment of an efficient antiviral response against influenza virus, we
silenced endogenous Riplet in WT or TRIM25 2/2 MEFs using
specific siRNA, and assessed influenza PR8 virus replication
(Figures 7D–7F). The knockdown of mRiplet was confirmed by
RT-PCR (Figure 7D). Infection of TRIM25 2/2 cells with PR8
virus resulted in higher plaque forming units (PFU) as compared
with WT MEF cells, underscoring the important role of TRIM25
for an efficient antiviral response in mouse. Furthermore, siRNA-
mediated knockdown of endogenous Riplet in both WT and
followed by IB with anti-Ub or anti-RIG-I antibody. (F) NS1 inhibits IFN-b induction in murine cells in a TRIM25-independent manner. WT and TRIM25
2/2 MEFs were transfected with an IFN-b luciferase construct together with empty vector or NS1. At 24 h posttransfection, cells were either mock-
treated, or infected with SeV (10 HA units/ml) for 16 h. Samples were then subjected to a dual luciferase assay. Data represent the mean 6 SD (n=3).
doi:10.1371/journal.ppat.1003059.g005
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replication compared to transfection of non-silencing siRNA, with
the strongest effect observed in TRIM25 2/2 MEFs in which
Riplet was silenced (Figure 7E). The increased virus replication in
Riplet-knockdown MEFs correlated with increased NS1 protein
levels in these cells (Figure 7F). Taken together, these data
demonstrate that both Riplet and TRIM25 contribute to an
effective antiviral response in mouse.
The NS1 Proteins from Human Influenza Viruses Bind and
Inhibit Human Riplet
Mice are not a natural host of influenza viruses, but the fact that
all NS1 proteins tested interacted with mouse Riplet, including
non-mouse adapted NS1 proteins (avian or swine) suggests that
this is a conserved evasion mechanism across influenza viruses.
Therefore, we tested if human Riplet interacts with the different
NS1 proteins in the context of viral infection. Interestingly, the
NS1 from human influenza viruses (Tx91 and Pan99) interacted
with human Riplet (Figure 8A), suggesting that the capacity of
NS1 binding to mouse Riplet might reflect an interaction of NS1
with Riplet derived from its specific host. To further demonstrate
that the interaction of NS1 with human Riplet is biologically
relevant, we compared the capacity of Tx91-NS1 and PR8-NS1
recombinant viruses to inhibit the ubiquitination of human RIG-I
(Figure 8B). We reasoned that Tx91-NS1 that binds both
hTRIM25 and hRiplet, should be more efficient in inhibiting
RIG-I ubiquitination (and IFN induction) than PR8-NS1 shown to
bind only hTRIM25. As predicted, Tx91-NS1 recombinant virus
was more efficient in inhibiting human RIG-I ubiquitination as
compared to PR8-NS1 virus (Figure 8B). Accordingly, Tx91-NS1
recombinant virus induced significantly lower levels of IFN-b
mRNA as compared to PR8 virus (Figure 8C). Finally, we
analyzed IFN-b production in PR8- and Tx91-infected A549 cells
upon knockdown of TRIM25, Riplet or both (Figures 8D and 8E).
siRNA-mediated knockdown reduced TRIM25 and Riplet mRNA
levels by approximately 90% and 80%, respectively. Furthermore,
the knockdown was highly specific, as targeting TRIM25 did not
reduce Riplet mRNA levels and vice-versa (Figure 8D). Silencing of
endogenous TRIM25 in PR8-infected cells resulted in a slight but
not significant decrease of IFN-b induction as compared to cells
Figure 6. Influenza A Virus NS1 interacts with mouse Riplet. (A) At 30 h posttransfection with Myc-tagged mouse Riplet (Myc-mRiplet)
together with NS1-PR8, HEK293T cells were mock-treated or infected with SeV (10 HA units/ml) for 10 h. V5-tagged hTRIM25 was co-transfected as
positive control. WCLs were subjected to IP with anti-Myc (Riplet) or anti-V5 (TRIM25), followed by IB with anti-NS1 antibody. (B) Hepa1.6 cells were
transfected with Flag-tagged mouse Riplet. At 30 h posttransfection, cells were either mock-treated or infected with recombinant A/PR/8/34 virus at
an MOI of 2. 18 h later, WCLs were subjected to IP with anti-NS1 antibody, followed by immunoblotting using the indicated antibodies. (C)
Localization of NS1-PR8 and mouse Riplet in HeLa cells determined by confocal microscopy. At 30 h posttransfection with Myc-mRiplet alone, NS1-
PR8 alone, or NS1 together with Myc-mRiplet, HeLa cells were stained with anti-Myc (green), anti-NS1 (red), and DAPI (nucleus, blue). Fifty cells from
three independent experiments were counted and the percentage of cells with cytoplasmic NS1 is shown, ***p,0.001 by Fisher’s exact test. (D and
E) Hepa1.6 cells were transfected with Flag-tagged mouse Riplet. At 30 h posttransfection, cells were either mock-treated or infected with
recombinant A/PR/8/34 virus expressing NS1 PR8, Cal04, HK156, Tx91, SwTx98, or Pan99 at an MOI of 2 (D), or R38A/K41A or E96A/E97A NS1 mutant
at an MOI of 4 (E). 18 h later, WCLs were subjected to IP with anti-NS1 antibody, followed by immunoblotting using the indicated antibodies.
doi:10.1371/journal.ppat.1003059.g006
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contrast, IFN induction by PR8 was significantly reduced in
Riplet-knockdown cells as compared to controls, and almost to the
same extent as the levels induced by the Tx91 virus in control cells.
These results suggest that while PR8 inhibits IFN induction by
targeting TRIM25, the residual IFN induction (not inhibited by
the virus) depends mostly on Riplet. Conversely, knockdown of
either TRIM25 or Riplet did not have a significant effect on IFN
induction in Tx91-infected cells. A significant reduction in IFN-b
mRNA levels was only observed in cells in which both TRIM25
and Riplet were silenced (Figure 8E). Collectively, these results
indicate that both TRIM25 and Riplet are important for IFN-b
production in human cells upon influenza virus infection.
Furthermore, while PR8-NS1 mainly targets TRIM25 in human
cells, Tx91-NS1 interacts with and suppresses both TRIM25 and
Riplet for the inhibition of IFN production in human cells.
Discussion
In this study we investigated the mechanisms by which the NS1
protein of influenza A viruses affects the TRIM25/RIG-I-
mediated type-I IFN response in different host species (Figure 9).
We demonstrated that NS1 proteins from avian and mammalian
isolates are capable of binding to human, but not mouse TRIM25.
In mouse cells, NS1 protein inhibits RIG-I ubiquitination and
downstream IFN promoter activation primarily by a mechanism
that involves binding to and inhibiting the ubiquitin E3 ligase
Riplet. This mechanism thus clearly differs from the previously
Figure 7. NS1 inhibits the Riplet-dependent RIG-I ubiquitination and IFN induction in murine cells. (A) Mouse Hepa 1.6 cells were
transfected with vector or Flag-tagged mRiplet with or without NS1-PR8. WCLs were subjected to IP with RIG-I antibody, followed by IB with anti-Ub
or anti-RIG-I antibody. Expression of mRiplet, NS1, and ubiquitin (Ub) was determined in the WCLs by IB with anti-Flag, anti-NS1 or anti-Ub antibody.
(B) Mouse Hepa1.6 cells were transfected with IFN-b luciferase reporter plasmid together with empty vector or mRIG-I together with or without
mRiplet and NS1-PR8. At 24 h posttransfection, cells were lysed and subjected to luciferase assay. Data shown is representative of 3 independent
experiments and depicted is the mean 6 SD (n=3). (C) Influenza NS1 protein specifically inhibits the Riplet-dependent ubiquitination of mouse RIG-I.
Hepa1.6 cells were transiently transfected with non-silencing control siRNA (si.C), or with a siRNA specific for mouse Riplet (si.Riplet) together with
empty vector or NS1-PR8. At 24 h posttransfection, cells were infected with SeV (50 HA units/ml) for 22 h. WCLs were used for IP with anti-RIG-I
antibody, followed by IB with anti-Ub or anti-RIG-I antibody. (D–F) Knockdown of endogenous Riplet in mouse embryonic fibroblasts enhances
influenza A virus replication. WT or TRIM25 2/2 MEFs were transfected with non-silencing control siRNA (si.C), or with a siRNA specific for mouse
Riplet (si.Riplet). At 30 h posttransfection, cells were infected with recombinant A/PR/8/34 WT virus (MOI 0.1). Knockdown of endogenous Riplet was
confirmed by RT-PCR (D). Supernatants were assayed for progeny virus yields 24 h postinfection in standard plaque titrations (E). Virus yields are
depicted in Pfu/ml. The results of three independent experiments are shown. Furthermore, viral NS1 protein expression was determined in the WCLs
of infected cells (F).
doi:10.1371/journal.ppat.1003059.g007
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cells. As mice are not natural hosts of influenza virus infection, we
reasoned that the ability of influenza virus NS1 to inhibit mouse
Riplet most likely reflects its inherent ability to inhibit Riplet from
other animal species. Indeed, our study showed that the NS1
protein of human viruses efficiently bound and suppressed human
Riplet, indicating that specifically human viruses have evolved to
inhibit both TRIM25 and Riplet for the suppression of RIG-I
antiviral activity in human cells. Interestingly, Riplet is highly
similar to TRIM25 sharing 60.8% sequence homology. Like
TRIM25, Riplet contains an N-terminal RING domain and a C-
terminal SPRY domain. However, in contrast to TRIM25, Riplet
does not contain a B-box domain and thus it does not belong to
the TRIM protein family [26]. Importantly, bioinformatic analysis
also predicted the presence of a central CCD in Riplet, with
structural similarities to the TRIM25 CCD (data not shown).
Further studies are needed to identify the precise binding site of
NS1 in Riplet, and whether this interaction requires the Riplet
CCD.
Furthermore, our interaction studies showed that an avian NS1
protein (HK156) strongly and preferentially interacted with
chicken TRIM25. Although RIG-I has been reported to be
absent in chicken cells [39], the fact that avian NS1 efficiently
interacted with chicken TRIM25 and that the HK156 virus was a
poor inducer of IFN in chicken cells, suggests that this interaction
is likely to be functional. In addition, we observed higher levels of
IFN induction in chicken cells by SwTx98 recombinant virus
correlating with the inability of its NS1 protein to bind chicken
TRIM25. Knockdown of TRIM25 in chicken cells resulted in
reduced IFN-b induction in infected cells, further evidencing that
TRIM25 is active and that NS1 targets its function in chicken
cells. Importantly, there are no Riplet sequences reported for the
chicken or duck genomes, suggesting that influenza A viruses that
are maintained in avian species have adapted to coexist with their
Figure 8. NS1 proteins from human influenza strains bind and inhibit human Riplet. (A) HEK293T cells were transfected with empty vector
or HA-tagged human Riplet (HA-hRiplet). At 30 h posttransfection, cells were either mock-treated, or infected with the indicated recombinant A/PR/8/
34 viruses at an MOI of 2. 18 h later, WCLs were subjected to IP with anti-HA antibody, followed by immunoblotting using the indicated antibodies.
(B) Tx91 recombinant virus suppresses the endogenous RIG-I ubiquitination more potently than PR8 virus. HEK293T cells, that had been transfected
with HA-tagged ubiquitin, were either mock-treated, or infected with DNS1 PR8, PR8 WT, or Tx91-NS1 recombinant virus at an MOI of 2 for 18 h.
WCLs were subjected to IP with anti-RIG-I antibody, followed by IB with anti-HA or anti-RIG-I antibody. Expression of HA-ubiquitin, viral NS1, and Actin
was further determined in the WCLs. (C) A549 cells were infected with PR8-NS1 or Tx91-NS1 recombinant virus at an MOI of 0.1. Cells were collected
at the indicated time points and IFN-b mRNA was measured by qPCR. (D and E) A549 cells were transiently transfected with non-silencing control
siRNA (si.C), or with siRNA specific for TRIM25 (si.TRIM25), Riplet (si.Riplet), or both. At 40 h posttransfection, cells were infected with PR8 WT or Tx91
recombinant virus at an MOI of 2 for 30 h. The mRNA levels of TRIM25 and Riplet were measured by qPCR for analyzing their knockdown efficiency
(D). Furthermore, IFN-b mRNA levels were assessed by qPCR (E). Results are triplicates from 3 independent experiments. NS; statistically non-
significant.
doi:10.1371/journal.ppat.1003059.g008
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studies will be required to elucidate the target of TRIM25 in
chicken, and whether the same principles apply to the natural
avian reservoir of influenza viruses, migratory ducks, which are
known to have RIG-I [39].
By studying RIG-I ubiquitination and signal-transducing
activity in murine cells, we have also uncovered commonalities
and differences between human and mouse RIG-I regulation.
Although Lys172, the critical residue for RIG-I ubiquitination in
human [25], is not conserved in mouse, we observed a robust
ubiquitination of mouse RIG-I 2CARD, suggesting that other
lysine residues in the mouse RIG-I CARDs are ubiquitinated.
Furthermore, our studies using TRIM25 2/2 cells indicate that
the ubiquitination of mouse RIG-I 2CARD, in contrast to that of
human RIG-I 2CARD, is less affected in the absence of TRIM25,
indicating that in addition to TRIM25 another ubiquitin E3 ligase
mediates RIG-I 2CARD ubiquitination in mouse. The ubiquitin
E3 ligase Riplet has been reported to ubiquitinate RIG-I, thereby
leading to its optimal activation [26,27,43]. However, while Riplet
has been shown to ubiquitinate Lys849 and Lys851 in the CTD of
RIG-I, the role of Riplet for RIG-I CARD ubiquitination has been
a subject of debate [26,27,43]. Our data suggests that, at least in
the mouse system, Riplet is unlikely to ubiquitinate the 2CARD,
because NS1 was unable to inhibit mouse RIG-I 2CARD
ubiquitination. Therefore, in addition to TRIM25 there may be
an additional ubiquitin E3 ligase in mice that ubiquitinates the
RIG-I N-terminal CARDs, and this E3 ligase is most likely not
targeted by NS1. Nevertheless, our studies clearly showed that
Riplet plays a crucial role for RIG-I ubiquitination-dependent
activation in mouse, most likely by ubiquitinating the C-terminal
region of RIG-I. Additional work will be needed to further define
the roles and contributions of these ubiquitin E3 ligases for RIG-I
activation in mouse.
For our interaction studies, we used NS1 proteins of influenza
viruses that are not able to bind CPSF30. This facilitates the
interpretation of the results, as their expression is not associated
with inhibition of general host protein expression. However, we
have also shown that the NS1 proteins of the Tx91 and Pan99
strains, which were previously shown to interact with CPSF30
[40], are also able to interact with human and mouse Riplet in
infected cells (Figures 6D and 8A). This suggests that NS1 binding
to Riplet or CPSF30 is not mutually exclusive.
The NS1 mutant E96A/E97A was previously reported to lack
human TRIM25 binding but retained dsRNA binding [38]. Our
results showed that the E96A/E97A NS1 mutant, but not the
R38A/K41A mutant, efficiently interacted with mouse Riplet,
suggesting that the region in NS1 important for dsRNA binding is
needed for interaction with mouse Riplet. Alternatively, the
interaction between NS1 and mouse Riplet could be mediated by
viral RNA.
In our previous study [38], we also showed that the PR8
recombinant virus carrying the E96A/E97A NS1 mutant was able
to induce IFN in WT and TRIM25 +/2 MEFs, but it lost this
IFN-inducing capacity in TRIM25 2/2 cells. In contrast, the
R38A/K41A NS1 recombinant virus and a PR8 virus lacking
NS1 (DNS1 PR8 virus) retained some IFN-inducing capacity in
TRIM25 2/2 cells [38]. Although we cannot completely rule out
that in our experiments a low affinity interaction between NS1 and
Figure 9. Proposed model of the species-specific inhibition of RIG-I by influenza A virus NS1 protein. The NS1 proteins of avian
influenza viruses bind to chicken TRIM25, thereby suppressing IFN induction. The substrate of TRIM25 in avian cells has yet to be determined. The
NS1 proteins from human influenza viruses bind to and inhibit both human TRIM25 and human Riplet, thereby suppressing the ubiquitination of the
RIG-I CARD and CTD. The NS1 proteins from avian, human and mouse-adapted influenza viruses block Riplet but not TRIM25 for the inhibition of RIG-I
signaling in mouse cells.
doi:10.1371/journal.ppat.1003059.g009
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the E96A/E97A mutant virus was able to repress the residual IFN
induction in TRIM25 2/2 cells [38] implies that this virus can, at
least in part, block IFN induction in mouse in a TRIM25-
independent manner. This probably occurs by binding dsRNA
and/or by interacting with other host factors including mouse
Riplet.
Our work raises an important question: why does NS1 target
Riplet instead of TRIM25 in mouse cells? Our results combined
with previous studies [25–27,43] suggest that although both
TRIM25 and Riplet contribute to optimal activation of both
mouse and human RIG-I, their requirement might be different in
human and mouse cells. Our experiments in TRIM25 2/2 cells
showed that whereas human RIG-I 2CARD ubiquitination is
undetectable in TRIM25 2/2 cells, mouse RIG-I 2CARD
showed residual ubiquitination under these conditions. In addi-
tion, knockdown of endogenous Riplet in mouse cells strongly
decreased RIG-I full-length ubiquitination. Taken together, this
suggests that while TRIM25 is the primary E3 ligase for human
RIG-I ubiquitination, in mouse other ubiquitin E3 ligases
including Riplet may play a crucial role for RIG-I ubiquitina-
tion-dependent activation. Under this scenario, in mouse cells NS1
must target Riplet for efficient inhibition of RIG-I signaling
(Figure 9). The mechanistic differences by how influenza virus
NS1 inhibits the RIG-I pathway in human and mouse cells
indicate that caution should be used to appropriately interpret
future experiments on host responses during influenza virus
infection using the mouse model.
Our study also identified two NS1 proteins from human viruses
(Tx91 and Pan99) which efficiently bound to human Riplet.
Furthermore, a recombinant virus expressing the Tx91 NS1
protein was more efficient in inhibiting endogenous RIG-I
ubiquitination and IFN induction in human cells as compared to
PR8 WT virus, whose NS1 protein does not bind human Riplet.
These results are in agreement with the high capacity of Tx91
virus to inhibit the antiviral state in human dendritic cells [44].
Combined with our knockdown analyses in A549 cells (Figures 8D
and 8E), this suggests that human viruses such as Tx91 have
evolved to interact with both TRIM25 and Riplet in human cells
for the comprehensive inhibition of the RIG-I-induced IFN
response (Figure 9).
Finally, although we have used representative strains from
different hosts, we cannot exclude that not all strains from a
specific host have the observed specificity of antagonism. Future
studies are needed to test NS1 proteins of various different strains
for their ability to inhibit TRIM25 and Riplet from multiple hosts,
and whether this correlates with the ability of these viruses to
suppress the IFN response in the respective host.
Taken together, our work suggests that influenza viruses can
readily adapt to circumvent the type-I IFN system in different host
species by targeting host-specific proteins involved in IFN
induction. It stresses the importance of host-specific signaling
pathways and immune responses when choosing animal models
for studying influenza pathogenicity. Understanding the changes
that viruses undergo during adaptation may provide us with better
tools to predict potential future pandemics and develop vaccines
and antivirals.
Materials and Methods
Cell Culture and Transfection
HEK293T (human), HeLa (human), A549 (human), Hepa1.6
(mouse), Vero, and L929 cells were purchased from the American
Type Culture Collection (ATCC). WT and TRIM25 2/2 MEFs
were previously described [25]. All cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 2 mM L-glutamine and 1%
penicillin-streptomycin (Gibco-BRL). The LMH (chicken) cells
were purchased from ATCC and cultured in flasks pre-coated with
0.1% gelatin in DMEM supplemented with 10% FBS, 2 mM L-
glutamine and 1% penicillin-streptomycin. Transient transfections
were performed with TransIT-LT1 (Mirus), calcium phosphate
(Clontech) or Lipofectamine 2000 (Invitrogen) according to the
manufacturers’ instructions.
Plasmids
Mammalian expression constructs for untagged NS1 under the
control of the chicken b-actin promoter (pCAGGS vector [45])
have been described previously for A/Puerto Rico/8/34 (PR8)
and R38A/K41A mutant NS1 [41]), A/Swine/Texas/4199-2/98
(Sw/Tx/98), A/Puerto Rico/8/34 E96A/E97A mutant, and A/
Hong Kong/156/1997 [38], and GST-PR8 and A/California/
04/09 NS1 (Cal04) [40]. Human TRIM25-V5, human RIG-I and
human GST-RIG-I 2CARD were described in [38]. Mouse
TRIM25 was cloned from murine LA-4 cells by Superscript III




CC-39). The forward primer includes an EcoRI site and V5
sequence, and the reverse primer includes a BamHI site. V5-
tagged mouse TRIM25 cDNA was then subcloned into the
EcoRI/BglII sites of the mammalian expression vector pCAGGS.
Chicken TRIM25 was cloned from primary chicken embryo
fibroblasts by Superscript III one-step RT-PCR with forward
primer (59- GAATTCACCATGGGCAAACCGATTCCGAAC-
CCGCTGCTGGGCCTGGATAGCACCGCGACGTTGACC
AAAGCTCAGTC-39) and reverse primer (59- GGCACTGT-
TCTCTCTCTCTGGTAACTCGAG-39). The forward primer
includes an EcoRI site and V5 sequence, and the reverse primer
includes a XhoI site. V5-tagged chicken TRIM25 cDNA was then
subcloned into the same sites of pCAGGS. For the generation of
V5-tagged human/mouse TRIM25 chimera, the coiled-coil
region of TRIM25 (aa191–379) was amplified using human
TRIM25-V5 plasmid as template, and then ligated into the BstBI
sites of the mouse TRIM25 sequence in the pCAGGS vector. The
Myc/DDK-tagged pCMV6 mouse Riplet was purchased from
Origene (Rockville, MD). The reporter plasmid carrying the firefly
luciferase (FF-Luc) gene under the control of the IFN-b promoter
(p125Luc) was kindly provided by Takashi Fujita (Kyoto
University, Japan) [46]. The reporter plasmid carrying the Renilla
luciferase gene (REN-Luc/pRL-TK) was purchased from Pro-
mega, WI. All sequences were verified by sequencing.
Viruses
Sendai virus (SeV; Cantell strain) was obtained from Charles
River Laboratories and propagated in 10-day old embryonated
chicken eggs. The A/Puerto Rico/8/1934 virus was propagated in
8-day old, specific pathogen-free embryonated eggs (Charles River
Laboratories; North Franklin, CT). Influenza virus titers were
determined by plaque assay using MDCK cells.
Rescue plasmids encoding the NS segments of A/Swine/
Texas/4199-2/98 and A/Hong Kong/156/1997, A/Texas/36/
1991 and A/Panama/2007/1999 were generated by cloning the
cDNA into the ambisense rescue plasmid pDZ [47]. The rescue
plasmid encoding A/California/4/2009 NS was described previ-
ously [48]. Isogenic influenza A viruses (A/Puerto Rico/8/1934)
harboring the NS segment of A/Swine/Texas/4199-2/98 or A/
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described elsewhere [38,49]. The A/Puerto Rico/8/1934 viruses
expressing the NS1 R38A/K41A or NS1 E96A/E97A mutant
were described previously [38]. All viruses were amplified in 8-day
old, specific pathogen-free embryonated hen’s eggs (Charles River
Laboratories; North Franklin, CT).
Interferon Bioassay
Interferon bioassays were conducted as described previously
[38,50]. Immortalized mouse embryonic fibroblasts (MEF), seeded
in 12-well plates, were infected with the indicated isogenic
influenza viruses at a multiplicity of infection (MOI) of 2. At
12 h postinfection, supernatants were harvested and 2-fold
dilutions of the influenza virus supernatants prepared. Diluted
supernatants were then applied to bioassay using immortalized
mouse fibroblast (L929) cells; At 20 h post-treatment, L929 cells
were infected with VSV-GFP at an MOI of 2. GFP fluorescence
was determined by fluorescence plate reader. Fluorescence values
are reported on the y-axis as relative fluorescence units.
GST Pull-Down Assay, Immunoprecipitation, and
Immunoblot Analysis
HEK293T, Hepa1.6 and MEF cells were lysed in NP40 buffer
(50 mM HEPES, pH 7.4, 150 mM NaCl, 1% [v/v] NP40 and
protease inhibitor cocktail [Roche]) or RIPA buffer (50 mM
TRIS-HCl pH 8.0, 150 mM NaCl, 1% [v/v] NP40, 0.5% sodium
deoxycholate, 0.1% SDS, and protease inhibitor cocktail [Roche]).
GST pull-down and immunoprecipitations were performed as
described previously [25]. For immunoblotting, proteins were
resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred onto a PVDF membrane (Immobilon-P Millipore
or BioRad Laboratories). The following primary antibodies were
used: anti-V5 (1:2,000) (Invitrogen), anti-Flag (1:5,000) (Sigma),
anti-HA (1:5,000) (Sigma), anti-GST (1:2,000) (Sigma), anti-
TRIM25 (monoclonal; 1:2,000) (BD Biosciences), anti-TRIM25
(polyclonal; 1:1,000) (Santa Cruz Biotechnology), anti-RIG-I
(1:1,000) (Alme-1, Alexis), anti-NS1 (1:2000) [38], anti-b-actin
(Abcam; Cambridge, MA). Immunoblots were developed with the
following secondary antibodies: ECL anti-rabbit IgG horseradish
peroxidase conjugated whole antibody from donkey, and ECL
anti-mouse IgG horseradish peroxidase conjugated whole anti-
body from sheep (GE Healthcare; Buckinghamshire, England).
The proteins were visualized by an enhanced chemiluminescence
reagent (Pierce).
Confocal Microscopy
HeLa cells were seeded into Lab-Tek II 8-well chamber slides
(CC2 Glass slide, Nunc; Rochester, NY). After 12–16 h, plasmids
harboring V5-tagged TRIM25, Myc-mRiplet, and/or NS1
plasmids were transfected with Lipofectamine 2000 (Invitrogen)
at a ratio 1:1. Six hours posttransfection the medium was changed.
24 h later, cells were washed with PBS, fixed with methanol-
acetone (1:1), permeabilized with 0.5% NP-40 (v/v) in PBS, and
blocked with 0.5% BSA 0.2% fish gelatin in PBS. Cells were
stained with anti-V5 or anti-Myc and anti-NS1 antibodies as well
as DAPI. Secondary antibodies conjugated to Alexa-fluor 488 and
Alexa-fluor 555 (Invitrogen) were used to visualize the proteins.
Images were taken on a Leica SP5 DM confocal microscope (Leica
Microsystems) at a magnification of 636. Confocal laser scanning
microscopy was performed at the MSSM-Microscopy Shared
Resource Facility.
IFN-b Luciferase Reporter Assay
Hepa1.6 cells, WT MEFs and TRIM25 2/2 MEFs were
transfected in 24-well plates (Falcon, Becton Dickinson, NJ) with
50 ng of IFN-b reporter plasmid, 20 ng of Renilla luciferase and
10 ng NS1 plasmids using Lipofectamine 2000 at a ratio 1:2. 24 h
later, cells were lysed and dual-luciferase assay was performed
according to the manufacturer’s instructions (Promega, Madison,
WI, USA). Luciferase values were normalized to Renilla values,
and the fold induction was calculated as the ratio of SeV-
stimulated samples, or samples transfected with inducing plasmid
versus samples transfected with empty plasmid (no stimulation).
Direct Protein Interaction Assay
Recombinant human TRIM25 (described in [25]) and mouse
TRIM25 purified from XL1blue bacteria as amino-terminal
Maltose-Binding Protein (MBP) and carboxy-terminal Flag fusion
proteins (MBP-h/mTRIM25-Flag) were incubated with bacteria-
produced recombinant GST or GST-NS1 (PR8) in 50 mM Tris
HCl, pH 7.4, 150 mM NaCl, and 0.1% NP40. TRIM25-NS1
protein complexes were then precipitated with Amylose agarose
resin (New England Biolabs), and the binding reaction mix was
incubated for 4 h at 4uC. Precipitated protein complexes were
resolved by SDS-PAGE and visualized by Coomassie staining.
siRNA-mediated Knockdown
Transient knockdown of endogenous Riplet in mouse Hepa 1.6
and MEF cells, seeded in 6-well plates, was achieved by
transfection of siGenome SMARTpool siRNA specific for mouse
Riplet (Dharmacon) with Lipofectamine and Plus reagent (In-
vitrogen) according to the manufacturer’s instructions. A final
concentration of 600 nM of mouse Riplet SMARTpool siRNA, or
600 nM of siGenome non-targeting siRNA (Dharmacon) was used
per well. Riplet knockdown efficiency was determined by RT-PCR
using specific primers.
Knockdown of endogenous human TRIM25 and Riplet in
A549 cells was performed in 24-well plates by transfection with
Lipofectamine RNAiMAX (Invitrogen). 10 picomols of siGenome
SMARTpool siRNA specific for human TRIM25 or Riplet, or
non-targeting control siRNA (Dharmacon) was used. 40 h later,
cells were infected with the different influenza viruses at an MOI
of 0.1 for 36 h. Cells were then harvested for qPCR analysis.
Knockdown of endogenous TRIM25 in chicken LMH cells
(hepatocellular carcinoma cell line), seeded in 24-well plates, was
achieved by transfection of a siRNA specific for chTRIM25 59-
GCGAGAUUUGCUGAGAGCUGAGUUU-39 (Invitrogen). As




Total RNA was isolated using RNeasy kit (Qiagen) and
subjected to DNAse digestion with Turbo DNase (Ambion).
Reverse transcription was performed using the high capacity
cDNA reverse transcription kit (Applied Biosystems). Real-time
RT-PCR was performed in 384-well plates in triplicate using gene-
specific primers and Lightcycler480 SYBR green I master mix
(Roche) in a Roche LightCycler 480. Threshold cycles were
calculated using the 2
nd derivative max value of every amplifica-
tion curve. Relative mRNA abundances were calculated using the
DDCt method [51] using 18S rRNA as a reference and plotted as
fold change compared to mock-control samples.
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Statistical analysis was performed using Prism (Version 5.0,
GraphPad Software, San Diego California USA). Student’s paired
t-test, or in defined cases Two-way ANOVA with Bonferroni post-
test or Fisher’s exact test were used. *p,0.05; **p,0.01;
***p,0.001.
Supporting Information
Figure S1 Amino acid sequence alignment of TRIM25
and NS1 proteins used in our study. (A) Protein sequence
alignment of the CCD of human (aa 211–353), mouse (aa 210–
351), and chicken (214–355) TRIM25 proteins. The amino acid
sequence of the TRIM25 CCDs was aligned using the Jalview
software [52]. Amino acids in dark blue are conserved in the three
sequences. Amino acids in light blue are identical in 2 out of 3
sequences. The predicted helical secondary structure, quality and
consensus sequence are depicted under the alignments. (B) Protein
sequence alignment of NS1 from human (A/California/04/09
[Cal04]), avian (A/Hong Kong/156/1997 [HK156]), swine (A/
Swine/Texas/4199-2/98 [SwTx98]) and mouse-adapted (A/
Puerto Rico/8/34 [PR8]) viruses. The amino acid sequence of
cloned NS1 proteins was aligned using ClustalW2 (http://www.
ebi.ac.uk/Tools/clustalw2/). Asterisks (*) indicate positions which
have a single, fully conserved residue. Colons (:) indicate
conservation between groups of strongly similar properties, and
periods (.) indicate conservation between groups of weakly similar
properties. The residues important for RNA binding and TRIM25
interaction are highlighted in blue and red, respectively [38].
Positions highlighted in grey indicate non-conserved amino acids.
(TIF)
Figure S2 Lys172 in the 2CARD of human RIG-I is not
conserved in mouse RIG-I. Protein sequence alignment of
mouse and human RIG-I 2CARD. Alignment was performed
using ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/). Aster-
isks (*) indicate positions which have a single, fully conserved
residue. Colons (:) indicate conservation between groups of
strongly similar properties, and periods (.) indicate conservation
between groups of weakly similar properties. Positions highlighted
in grey indicate non-conserved amino acids.
(TIF)
Figure S3 Lys849 and Lys851 of human RIG-I are
conserved in mouse RIG-I. Protein sequence alignment of
the C-terminal domain (CTD) of mouse and human RIG-I.
Alignment was performed using ClustalW2 (http://www.ebi.ac.
uk/Tools/clustalw2/). Positions highlighted in grey indicate non-
conserved amino acids.
(TIF)
Figure S4 (A) Endogenous RIG-I ubiquitination is
markedly decreased upon influenza infection in WT
and TRIM25 2/2 MEFs. WT and TRIM25 2/2 MEFs were
either mock-treated or infected with PR8 (MOI of 2) for 18 h.
WCLs were subjected to IP with anti-RIG-I antibody, followed by
IB with anti-Ub or anti-RIG-I antibody. (B) Interaction of NS1
with mouse Riplet. WCLs of mouse Hepa1.6 cells transfected
with empty vector or Myc-tagged mouse Riplet (Myc-mRiplet)
together with NS1-PR8, NS1-Cal04 or NS1-HK156 were
subjected to IP with anti-Myc antibody, followed by IB with
anti-NS1 or anti-Myc. (C) The NS1 E96A/E97A mutant but
not the R38A/K41A mutant interacts with mouse Riplet.
At 30 h posttransfection with empty vector or Myc-tagged mouse
Riplet (Myc-mRiplet) together with NS1-PR8 R38A/K41A or
E96A/E97A mutant, HEK293T WCLs were subjected to IP with
anti-Myc antibody, followed by IB with anti-NS1 antibody.
(TIF)
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